Sign Up Today and Learn More About Synthorx Stock
Invest in or calculate the value of your shares in Synthorx or other pre-IPO companies through EquityZen's platform.
About Synthorx Stock
Founded
2014
Headquarters
La Jolla, CA, US
Total Funding
79.0M
Industries
Software, Artificial Intelligence, Data and Analytics
Synthorx is a biotechnology company using ground-breaking synthetic biology starting with our novel DNA base pair to discover and develop new protein therapeutics. The company uses new building blocks to create proteins that impart specificity not possible with native proteins. The result is treatments with improved efficacy, better safety, and better convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture these improved proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies.
Synthorx Press Mentions
Stay in the know about the latest news on Synthorx
Sanofi Chief Signals Focus on Cancer With $2.5 Billion Deal
Wall Streets Journal • Dec 09, 2019
Synthetic Biology Market is Determined to Cross US$ 38 Billion By 2020
Herald Keeper • Jun 12, 2018
BRIEF-Synthorx Completes $63 Mln Series C Financing Led By OrbiMed
Reuters • Apr 30, 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines
• Apr 30, 2018
Laura Shawver hits the ground running, scouting new investors for tiny Synthorx
Endpoints News • Dec 01, 2017
Investors in Synthorx
Discover investors in Synthorx stock and explore their portfolio companies
Synthorx Management
Leadership team at Synthorx
Chief Scientific Officer
Marcos Milla
President and CEO
Laura Shawver
Join now and verify your accreditation status to gain access to:
- Synthorx current valuation
- Synthorx stock price
- Available deals in Synthorx and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Synthorx Stock
How to invest in Synthorx stock?
Accredited investors can buy pre-IPO stock in companies like Synthorx through EquityZen funds. These investments are made available by existing Synthorx shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Synthorx stock?
Shareholders can sell their Synthorx stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
